China Blood Products Industry Report, 2010-2011

Sep. 2011
This report

◆ Analyzes China blood products market

◆ Focuses on blood products market segment

◆ Highlights the operation of key blood products manufacturers in China.

Related Products

<table>
<thead>
<tr>
<th>China Human Vaccine Industry Report, 2010-2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>China Oral Hypoglyceimic Agents (OHAs) Industry Report, 2010</td>
</tr>
<tr>
<td>China Interventional Cardiovascular Device Industry Report, 2010</td>
</tr>
<tr>
<td>China Insulin Industry Report, 2010</td>
</tr>
<tr>
<td>China Medical Imaging Device Industry Report, 2010</td>
</tr>
<tr>
<td>China Medical Monitor Industry Report, 2010</td>
</tr>
</tbody>
</table>

Please visit our website to order this report and find more information about other titles at www.researchinchina.com
Abstract

Recent years have seen fast-growing development of blood product industry in China, with the enterprises concerned numbering 33 which can produce 10-odd blood products including human albumin, human immunoglobulin (pH4) for intravenous injection and human immunoglobulin. In 2003-2010, the CAGR of blood products reached 20.3% in China, far above the global level in the same period.

Thanks to many favorable factors such as the advance of economy and technology, the acceleration of population growth and aging process as well as the people’s further recognition of blood products, China’s blood product market has seen buoyant momentum which is expected to maintain until 2015 and beyond.

However, the blood products of China have always seen short supply due to limited blood plasma source. Especially, since August 2011 when 16 plasma collection stations were closed in Guizhou Province, the production of China-based blood product enterprises has been further constrained.
As for recombinant coagulation factor VIII, due to high price and policy restriction (it’s only allowed to use when hemophilia patients suffer serious bleeding and human coagulation factor VIII is unavailable), only products made by Bayer are allowed to be imported in China. However, considering the scarcity of human coagulation factor VIII and the increasing demand for coagulation factor VIII, the demand for recombinant coagulation factor VIII will grow further in China.

Accounting for five of the 16 plasma collection stations closed in Guizhou, Hualan Biological Engineering is the biggest victim of the shutdown, but it still comes out top in terms of the number of blood plasma stations (numbering 13), followed by Shanghai RAAS Blood Products and Beijing Tiantan Biological Products Corporation.

The supply shortage of blood products coupled with strained blood plasma source of leading enterprises has propelled China’s import of blood products, but, thus far, only human albumin and recombinant coagulation factor VIII are allowed to import from foreign countries.

Affected by the lower price of human albumin in foreign countries, China has long been increasing its import volume, with the proportion in 2010 reaching 48.4% (by lot release volume), up 7.2% year-on-year. In particular, Octapharma and Behring occupied the biggest chunk.
### Table of contents

#### 1. Overview of Blood Products Industry
- 1.1 Definition of Blood Products
- 1.2 Classification of Blood Products
- 1.3 Recombinant Blood Products
- 1.4 Blood Product Industry Chain
- 1.5 Features of Blood Products

#### 2. Overview of China Blood Products Industry
- 2.1 Market Size
- 2.2 Development Status
- 2.3 Supply & Demand
- 2.4 Market Competition
- 2.5 Operating Environment
  - 2.5.1 International Market
  - 2.5.2 Policies
- 2.5.3 Domestic Biopharmaceutical Market
- 2.6 Import & Export

#### 3. Blood Products Market Segments in China
- 3.1 Human Albumin
  - 3.1.1 Supply & Demand
  - 3.1.2 Competition Pattern
  - 3.1.3 Prospects
- 3.2 Human Immunoglobulin (pH4) for Intravenous Injection
  - 3.2.1 Competition Pattern
- 3.3 Coagulation Factor
  - 3.3.1 Supply & Demand
  - 3.3.2 Competition Pattern
  - 3.3.3 Prospects

- 3.4 Hepatitis B Immunoglobulin
  - 3.4.1 Supply & Demand
  - 3.4.2 Competition Pattern
- 3.5 Human Immunoglobulin
  - 3.5.1 Competition Pattern
- 3.6 Human Prothrombin Complex
  - 3.6.1 Competition Pattern
- 3.7 Tetanus Immunoglobulin
  - 3.7.1 Competition Pattern
- 3.8 Rabies Immunoglobulin
  - 3.8.1 Competition Pattern

#### 4. Key Manufacturers in China
- 4.1 Hualan Biological Engineering Ltd
  - 4.1.1 Profile
  - 4.1.2 Operation
- 4.2 Shanghai RAAS Blood Products Co., Ltd
  - 4.2.1 Profile
  - 4.2.2 Operation
- 4.3 Beijing Tiantan Biological Products Co., Ltd
  - 4.3.1 Profile
  - 4.3.2 Operation
- 4.4 China Biologic Products, Inc
  - 4.4.1 Profile
  - 4.4.2 Operation

- 4.4.3 Shandong Taibang Biological Products Co. Ltd
- 4.4.4 Xi’an Huitian Blood Products Co. Ltd
- 4.4.5 Guiyang Qianfeng Biological Product Liability Co., Ltd
- 4.5 Jiangxi Boya Biopharmaceutical Co., Ltd
  - 4.5.1 Profile
  - 4.5.2 Operation
- 4.6 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd
  - 4.6.1 Profile
  - 4.6.2 Operation
- 4.7 CNBG Shanghai Institute of Biological Products
  - 4.7.1 Profile
  - 4.7.2 Operation
  - 4.7.3 Prospects
- 4.8 Shanxi Kangbao Biological Product Co., Ltd
  - 4.8.1 Profile
  - 4.8.2 Operation
- 4.9 Green Cross
  - 4.9.1 Profile
  - 4.9.2 Operation
Selected Charts

- Basic Components of Blood
- Classification and Effects of Blood Products
- Comparison between Gene Recombinant Blood Products and Traditional Blood Products
- Categories and Comparison of Recombinant Blood Products in China and Worldwide
- Blood Product Industry Chain
- Product Structure of Blood Products in China (by Lot Release Volume), 2009-2010
- Annual Plasma Volume in China, 2002-2010
- Geographical Distribution of Plasma Collection Station Resources in China, Aug.2011
- Comparison of Per Capita Usage of Blood Products between China and Developed Countries
- Market Share of Major Manufacturers of Blood Products in China, 2010
- Comparison among Blood Product Manufacturing Enterprises in China by Product Line
- Production of Blood Product Manufacturing Enterprises in China, Aug.2011
- Global Blood Product Market Scale, 2003-2010
- Blood Products in Overseas Countries
- On-going Clinical Trial of New Indications Overseas
- Global Blood Product Manufacturing Enterprises
- Operation of International Blood Product Giants, 2010
- Major Policies for Blood Products in China
- Sales and YoY Growth Rate of Biological and Biochemical Pharmaceuticals in China, 2005-H1 2011
- Supply and Demand of Human Albumin Worldwide, 2010
- Ratio of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2010
- Market Share of Major Manufacturers of Domestic Human Albumin (by Lot Release Volume), 2007-2010
- Market Share of Major Manufacturers of Imported Human Albumin (by Lot Release Volume), 2007-2010
• Comparison between China and USA by Consumption of Human Immunoglobulin (pH4) for Intravenous Injection, 2010
• Lot Release Volume and Its Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2010
• Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection (by Lot Release Volume), 2007-2010
• Lot Release Volume and Its Growth Rate of Coagulation Factor VIII in China, 2008-2010
• Market Share of Major Manufacturers of Coagulation Factor VIII in China (by Lot Release Volume), 2008-2010
• Comparison between Human-derived Coagulation Factor VIII and Recombinant Coagulation Factor VIII
• Lot Release Volume and Its Growth Rate of Hepatitis B Immunoglobulin in China, 2008-2010
• Market Share of Major Manufacturers of Hepatitis B Immunoglobulin (by Lot Release Volume), 2008-2010
• Release Volume and Its Growth Rate of Human Immunoglobulin in China, 2008-2010
• Major Manufacturers and Their Shares in Chinese Human Immunoglobulin Market (by Lot Release Volume), 2008-2010
• Release Volume and Its Growth Rate of Human Prothrombin Complex in China, 2008-2010
• Manufacturers and Their Shares in Chinese Human Prothrombin Complex Market (by Lot Release Volume), 2008-2010
• Lot Release Volume and Its Growth Rate of Tetanus Immunoglobulin in China, 2008-2010
• Market Share of Major Manufacturers in Chinese Tetanus Immunoglobulin Market (by Lot Release Volume), 2008-2010
• Lot Release Volume and Its Growth Rate of Rabies Immunoglobulin in China, 2008-2010
• Market Share of Major Manufacturers in Chinese Rabies Immunoglobulin Market (by Lot Release Volume), 2008-2010
• Operating Revenue and Net Income of Hualan Biological Engineering Ltd, 2007-H1 2011
• Operating Revenue of Hualan Biological Engineering Ltd (by Sector), 2007-2010
• Gross Margin of Hualan Biological Engineering Ltd (by Product), 2007-2010
• Operating Revenue of Hualan Biological Engineering Ltd (by Region), 2007-2010
• Distribution of Plasma Collection Stations of Hualan Biological Engineering Ltd, Aug.2011
• Operating Revenue of Blood Products of Hualan Biological Engineering Ltd (by Product), 2007-2010
• Operating Revenue of Blood Products of Hualan Biological Engineering Ltd (by Product), 2007-2010
• Operating Revenue and Net Income of Shanghai RAAS Blood Products Co., Ltd, 2007-H1 2011
• Operating Revenue of Shanghai RAAS Blood Products Co., Ltd (by Product), 2005-2010
• Gross Margin of Shanghai RAAS Blood Products Co., Ltd (by Product), 2005-2010
• Operating Revenue of Shanghai RAAS Blood Products Co., Ltd (by Region), 2008-2010
• Distribution of Plasma Collection Stations of Shanghai RAAS Blood Products Co., Ltd, Aug.2011
• Plasma Volume of Shanghai RAAS Blood Products Co., Ltd, 2007-2011E
• Operating Revenue and Net Income of Beijing Tiantan Biological Products Co., Ltd, 2007-Q1 2011
• Operating Revenue of Beijing Tiantan Biological Products Co., Ltd (by Product), 2007-2010
• Gross Margin of Beijing Tiantan Biological Products Co., Ltd (by Product), 2007-2010
• Operating Revenue of Beijing Tiantan Biological Products Co., Ltd (by Region), 2007-2010
• Operation of Chengdu Rongsheng Pharmaceuticals Co., Ltd, 2008-2009
• Distribution of Blood Plasma Collection Stations of Chengdu Rongsheng Pharmaceuticals Co., Ltd, Aug.2011
• Operating Revenue and Gross Profit of China Biologic Products, Inc, 2007-H1 2011
• Operating Revenue of Blood Products of China Biologic Products, Inc (by Product), 2007-2010
• Operating Revenue and Total Profit of Shandong Taibang Biological Products Co. Ltd, 2008-2009
• Operating Revenue and Total Profit of Xi’an Huitian Blood Products Co. Ltd, 2008-2009
• Operating Revenue and Total Profit of Guiyang Qianfeng Biological Product Liability Co., Ltd., 2008-2009
Selected Charts

- Operating Revenue and Net Income of Jiangxi Boya Biopharmaceutical Co., Ltd., 2008-2010
- Operating Revenue of Jiangxi Boya Biopharmaceutical Co., Ltd. (by Product), 2008-2010
- Gross Margin of Jiangxi Boya Biopharmaceutical Co., Ltd. (by Product), 2008-2010
- Prices Trend of Blood Products of Jiangxi Boya Biopharmaceutical by Product, 2008-2010
- Plasma Volume of Plasma Collection Stations of Jiangxi Boya Biopharmaceutical, 2008-2010
- R & D Investment and the Proportion in Sales of Jiangxi Boya Biopharmaceutical, 2008-2010
- Blood Product R & D Projects and Progress of Jiangxi Boya Biopharmaceutical, July 2011
- Operating Revenue and Total Profit of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd, 2008-2009
- Operation of CNBG Shanghai Institute of Biological Products, 2008-2009
- Blood Product List of CNBG Shanghai Institute of Biological Products, Jul.2011
- Distribution of Plasma Collection Stations of CNBG Shanghai Institute of Biological Products, Aug.2011
- Operation of Shanxi Kangbao Biological Products Co., Ltd, 2008-2009
- Operation of Green Cross (China), 2008-2009
- Blood Product List of Green Cross (China), Jul.2011
You can place your order in the following alternative ways:

1. Order online at www.researchinchina.com
2. Fax order sheet to us at fax number:+86 10 82601570
3. Email your order to: report@researchinchina.com
4. Phone us at +86 10 82600828/ 82600893

<table>
<thead>
<tr>
<th>Party A:</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Name:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Person:</td>
<td>Tel</td>
<td></td>
</tr>
<tr>
<td>E-mail:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Party B:</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Name: Beijing Waterwood Technologies Co., Ltd (ResearchInChina)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address: Room 1008, A2, Tower A, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Person: Liao Yan</td>
<td>Phone: 86-10-82600828</td>
<td></td>
</tr>
<tr>
<td>E-mail: <a href="mailto:report@researchinchina.com">report@researchinchina.com</a></td>
<td>Fax: 86-10-82601570</td>
<td></td>
</tr>
</tbody>
</table>

Bank details:
Beneficial Name: Beijing Waterwood Technologies Co., Ltd
Bank Name: Bank of Communications, Beijing Branch
Bank Address: NO.1 jinxiyuan shijicheng, Landianchang, Haidian District, Beijing
Bank Account No #: 110060668012015061217
Routing No #: 332906
Bank SWIFT Code: COMMCNSHBJG

<table>
<thead>
<tr>
<th>Title</th>
<th>Format</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hard copy</td>
<td>…………………………2100 USD</td>
<td></td>
</tr>
<tr>
<td>PDF (Single user license)</td>
<td>………......2000 USD</td>
<td></td>
</tr>
<tr>
<td>PDF (Enterprisewide license)</td>
<td>……. .... 3000 USD</td>
<td></td>
</tr>
</tbody>
</table>

※ Reports will be dispatched immediately once full payment has been received.
Payment may be made by wire transfer or credit card via Paypal.